ConvaTec sets November 18 update: UBS sees 6.00 percent growth for ConvaTec stock

Published on 10/20/2026 at 18:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue rose 4.40 percent to USD 1.232 billion. ConvaTec stock costs EUR 2.84 on October 20, 2026, up 0.71 percent versus Tradegate close.

Reporting date November 18, 2026

UBS expects 6.00 percent organic growth for the second half in its October 19, 2026 assessment.
ConvaTec reported H1 2026 revenue of USD 1.232 billion, up 4.40 percent year over year.
ConvaTec stock costs EUR 2.84 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST, 0.71 percent above the Tradegate close and 9.22 percent below the 52-week high.
The company is scheduled to publish its preliminary fiscal year 2026 results on February 23, 2027.

Editorialfoto vom Handelssaal der Londoner Börse mit Gesundheitssektor-Charts — ConvaTec Group Plc GB00BD3VFW73 zeigt Börsen-Editorial vom Handelssaal der London Stock Exchange mit Gesundheitssektor-Charts, Illustration mit AI erstellt.

ConvaTec scheduled its 10-month trading update for November 18, 2026, while UBS expects 6.00 percent organic growth for the second half, according to Investing.com on October 19, 2026. The date appears in the company results calendar carried by Investegate. ConvaTec stock was trading at EUR 2.84 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST, up 0.71 percent versus the Tradegate close of October 16, 2026 at EUR 2.82.

What will November 18 test?

UBS expects 6.00 percent organic growth for ConvaTec in the second half and sees full-year guidance of 5.50 percent to 6.50 percent being reiterated, excluding InnovaMatrix. The same assessment points to a 23.00 percent margin. The trading update will therefore put the companys growth delivery and margin path ahead of fiscal year 2027 under scrutiny.

H1 growth came with margin pressure

For the six months ended June 30, 2026, ConvaTec reported revenue of USD 1.232 billion, up 4.40 percent from USD 1.180 billion a year earlier. Adjusted operating profit increased 3.90 percent to USD 262.00 million, while adjusted operating margin was 21.20 percent versus 21.30 percent in the comparable period, according to Investegate.

The reported operating result was USD 115.00 million, down 36.10 percent year over year, including a USD 69.00 million non-cash impairment linked to InnovaMatrix. That contrast makes the adjusted margin and the companys second-half execution central to the November update.

Stock remains below its yearly high

On the London Stock Exchange, ConvaTec was last at GBp 235.40 on October 20, 2026 at 4:49 p.m. London time. The 52-week range was GBp 193.00 to GBp 259.30, placing the share 9.22 percent below its high and 21.97 percent above its low. The market capitalization was GBP 4.5 billion and the trailing P/E was 50.45.

The next dates are clear

The next scheduled event is the 10-month trading update on November 18, 2026. The companys preliminary fiscal year 2026 results are scheduled for February 23, 2027, according to Investegate. Separately, an RNS filing showed BlackRock held 5.39 percent of voting rights after crossing the threshold on October 16, 2026, according to Investor Meet Company.

Price and operating signals

ConvaTec combines mid-single-digit reported revenue growth with a relatively stable adjusted margin, but its reported operating profit shows the effect of the InnovaMatrix impairment. The November update will provide the next dated test of whether stronger second-half growth can support the margin target.

ConvaTec stock was trading at EUR 2.84 at Lang & Schwarz on October 20, 2026 at 6:36 p.m. CEST, 0.71 percent above the Tradegate close of October 16, 2026 at EUR 2.82. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.